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Ski Promotes Tumor Growth Through Abrogation
of Transforming Growth Factor- Signaling in
Pancreatic Cancer
T. Ryan Heider, MD,* Suzanne Lyman, MS,* Robert Schoonhoven, MS,‡ and Kevin E. Behrns, MD†
Objective: We hypothesized that human pancreatic cancer resists
TGF- signaling and cell death through increased Ski expression.
Summary Background Data: Ski is an oncogenic protein that acts
as a TGF- repressor and prevents related gene transcription. Pre-
vious work suggests that Ski acts as an oncoprotein in melanoma
and esophageal cancer. Ski expression and function have not been
determined in human pancreatic cancer.
Methods: Immunohistochemistry and immunoblots assessed Ski
expression in human pancreatic cancer. Panc-1 cells were treated
with or without Ski siRNA, and Ski and Smad protein expression,
transcriptional reporter activation, and growth assays were deter-
mined. Panc-1 cells were inoculated in the flank of nude mice and
tumor volume and histology assessed after administration of Ski
siRNA or control vector.
Results: Ski was abundantly expressed in human pancreatic cancer
specimens assessed by immunohistochemistry (91%) and immuno-
blot analysis (67%). Panc-1 cells exhibited nascent Ski expression
that was maximally inhibited 48 hours after transfection with Ski
siRNA. TGF- transcriptional activity was increased 2.5-fold in Ski
siRNA-treated cells compared with control (P  0.05). Ski siRNA
increased TGF--induced Smad2 phosphorylation and p21 expres-
sion. Panc-1 growth in culture was decreased 2-fold at 72 hours. A
Ski siRNA expression vector injected into nude mice resulted in a
5-fold decrease in growth.
Conclusion: Inhibition of Ski through RNA interference restored
TGF- signaling and growth inhibition in vitro, and decreased tumor
growth in vivo.
(Ann Surg 2007;246: 61–68)
The nearly equivalent annual incidence and mortality ratefor adenocarcinoma of the pancreas provides direct evi-
dence of the difficulty in treating this late-presenting malig-
nancy.1 Surgical resection remains the only definitive chance
at long-term survival, but only 10% to 20% of patients with
pancreatic adenocarcinoma present with resectable disease.2
Therefore, the majority of patients present with advanced
local-regional or metastatic disease that is treated by chemo-
therapy and/or radiation therapy with a potential 3- to
6-month survival benefit and an overall 5-year survival rate of
5%.2 Chemoresistance of pancreatic carcinoma is the sub-
ject of intense investigation aimed at uncovering mechanisms
of resistance to cell death. These efforts, however, have been
hindered by lack of a complete understanding of the complex
molecular carcinogenesis of pancreatic adenocarcinoma.
Recent basic science investigation has improved our
understanding of the molecular genetics of pancreatic cancer
in that histologic identification of pancreatic intraepithelial
neoplasia (PanIN), precursor lesions to pancreatic carcinoma,
has been correlated with genetic alterations such that a
progressive model of pancreatic carcinogenesis has been
proposed.3,4 Although a number of molecular changes have
been described, the most common mutations occur in the
oncogenes KRAS2 and ERBB2, the tumor suppressor genes
p16/CDKN2A, TP53, and MADH4 (Smad4), and the DNA
repair gene BRCA2. KRAS2 mutations are predominant
(90%) in pancreatic cancer and appear to occur early in the
development of precursors lesions whereas loss of tumor
suppressor function from p16/CDKN2A inactivation occurs
somewhat less frequently (80%) and later in the sequence
of oncogenesis.3–7 Loss of TP53 and MADH4 function are
late events in pancreatic carcinogenesis and occur in approx-
imately 70%8 and 55%3 of pancreatic cancers, respectively.
Loss of MADH4 function, herein referred to as Smad4,
impairs signaling of the growth-inhibitory transforming
growth factor beta (TGF-) and bone morphogenetic protein
signal transduction pathways by inhibiting DNA binding
activity of Smad pathway mediators to Smad binding ele-
ments in target growth-control genes.
TGF- is a multifunctional cytokine that possesses a
variety of important antitumor effects, including the induc-
tion of apoptosis, cell cycle arrest, inhibition of angiogenesis,
and tumor surveillance. The TGF- signal is conveyed to the
nucleus by binding of the TGF- ligand to its receptors,
phosphorylation of Smads2/3, heterotrimeric assembly of
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Smads2/3 with Smad4, and subsequent migration to the
nucleus with induction into gene transcription.8,9 In addi-
tion to mutations in Smad4 in pancreatic cancer, down-
regulation and/or mutation of the type II TGF- receptor
has been described.11,12 Furthermore, inactivation of p53
may influence TGF- signaling since p53 has been re-
cently identified as an essential cofactor for effective Smad
signaling.13 Additionally, in vitro studies in a Smad4-null
cell line have shown that TGF- growth inhibitory re-
sponses do not require Smad4 expression, suggesting that
TGF- mediated effects can be conveyed through multiple
growth control pathways.14 Collectively, these findings
suggest that the molecular pathways in pancreatic carci-
nogenesis are complex and may interact extensively to
produce phenotypic growth characteristics.
To add to the complexity of TGF- signaling, recent
evidence has shown that expression of the oncoprotein, Ski, is
evident in several human malignancies. The magnitude of ex-
pression is correlated with tumor progression in melanoma,15
esophageal,16 and colorectal cancers.17 Ski is a proto-onco-
gene that negatively regulates TGF- signaling and is capable
of transforming and inducing anchorage-independent growth
of chicken embryo fibroblasts.18 Ski physically binds to the
common elements Smad2 and 3 but has also been shown to
inhibit TGF- signaling through inhibition of Smad2 phosphor-
ylation,19 cytoplasmic sequestration of Smad complexes,20 and
prevention of the Smad 2/3/4 complex formation with essential
nuclear cofactors.21 However, Ski’s role in abrogating TGF-
signaling and inhibiting tumor growth in pancreatic cancer is
unknown. Therefore, the aim of this study was to determine
if Ski is expressed in human pancreatic cancer and to examine
mechanisms by which Ski may regulate pancreatic cancer
growth responses to TGF-.
MATERIALS AND METHODS
Reagents and Antibodies
The following materials were purchased from the man-
ufacturer: mouse monoclonal anti Cip-1/WAF-1/p21 (Pharm-
ingen, San Diego, CA), mouse monoclonal anti--actin
AC-15 (Sigma), goat polyclonal anti-Smad 2/3 (N-19) (Santa
Cruz Biotechnology, Santa Cruz, CA), rabbit polyclonal
antiphospho-Smad 2 (Ser465/467) (Cell Signaling, Beverly,
MA), rabbit polyclonal anti-Ski (Upstate, Lake Placid, NY),
peroxidase-conjugated anti-rabbit, antimouse and anti-goat
IgG, R-phycoerythrin-conjugated donkey anti-rabbit IgG
(Jackson Immunoresearch, West Grove, PA), and recombi-
nant human TGF-1 (R&D Systems, Minneapolis, MN). The
p3TP-luciferase construct with 3 TGF--responsive elements,
a plasminogen activator inhibitor-1 (PAI-1) promoter,22 and an
upstream adenoviral E4 promoter was a gift from Dr. Richard
A. Rippe (Chapel Hill, NC). Animal use and care was
approved by the University of North Carolina Institutional
Animal Care and Use Committee.
Human Tissue Specimens
Tumor specimens from 20 total patients who had un-
dergone resection for pancreatic adenocarcinoma were ana-
lyzed for Ski expression by immunohistochemistry or immu-
noblot. Pancreatic tissue from 5 patients with chronic
pancreatitis and 9 normal pancreatic specimens were used for
comparative purposes.
Immunoblot Analysis
For whole cell extracts, cells were rinsed twice in PBS
and lysed in buffer containing 0.05 mol/L Tris, pH 7.3, 0.15
mol/L NaCl, 1% NP40, 0.5% deoxycholate, for 10 minutes at
4°C. Samples were centrifuged at 14,000 rpm to remove
debris and the protein concentration was determined by
Bradford assay. After SDS-polyacrylamide gel electrophore-
sis, samples were transferred to PVDF membranes and
blocked in 5% nonfat milk in TBS-T. After incubation with
rabbit polyclonal anti-Ski antibody, the antibody was diluted
1:1000 in blocking buffer for 1 hour, blots were washed for
15 minutes in TBS-T, incubated with HRP-conjugated sec-
ondary antibody (1:1000) for 30 minutes and visualized by
enhanced chemiluminescence (Amersham Biosciences, Pis-
cataway, NJ).
Cellular extracts were obtained by lysis in buffer con-
taining 10 mmol/L HEPES, pH 7.9, 1.5 mmol/L MgCl2, 10
mmol/L KCl, 0.1% Triton X-100, 0.5 mmol/L DTT, and 0.5
mmol/L protease and phosphatase inhibitor cocktails (Sigma
Aldrich, St. Louis, MO). The cytoplasmic fraction was col-
lected and the nuclear pellet was resuspended in a buffer
containing 20 mmol/L HEPES, pH 7.9, 1.5 mmol/L MgCl2,
0.42 M NaCl, 0.2 mmol/L EDTA, 1% NP40, 25% glycerol,
0.5 mmol/L DTT, and 0.5 mmol/L protease inhibitor cocktail.
Immunohistochemistry
Sections (5 m) of formalin-fixed samples were depar-
affinized with xylene and rehydrated through graded alcohol
into distilled water. Sections were subjected to heat-induced
epitope retrieval in target unmasking fluid (Zymed Labora-
tories, Inc., San Fransisco, CA) prior to staining. Sections
were rinsed in PBS with 1% Tween 3 times, incubated with
primary antibody (1:100 in 1% BSA) for 30 minutes, rinsed
3 times, and incubated with secondary antibody for 30 min-
utes. Endogenous phosphatase activity was blocked with 5
mmol/L levamisole, and the alkaline-phosphatase based chro-
mogen was applied as directed by the manufacturer (New
Fuchsin, BioGenex, San Ramon, CA). Sections were coun-
terstained with hematoxylin, mounted, and visualized via
light microscopy. Antibody staining was quantified by digital
image analysis (BioQuant Image Analysis Corp., Nashville,
TN).
Transcriptional Reporter Assay
Cells were seeded at a density of 2  105 in 6-well
plates the day prior to sequential transfection with 5 g of
siRNA using RNAiFect (Qiagen Inc., Valencia, CA) and 4
g of p3TP-luciferase DNA using Lipofectamine 2000 (In-
vitrogen, Carlsbad, CA). After 24 hours of treatment, cells
were harvested for luciferase expression using the Dual-
Luciferase Reporter Assay System (Promega Corporation,
Madison, WI) according to manufacturer’s instructions and
analyzed using a Monolight 2010 Luminometer (Analytical
Luminescence Laboratory, San Diego, CA).
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Cell Culture and siRNA Transfection
Panc-1 cells were obtained from the American Type
Tissue Collection (Manassas, VA) and maintained in Dul-
becco Modified Eagle Medium with 4mmol/L L-glutamine
and adjusted to contain 4.5 g/L glucose and 1.5 g/L sodium
bicarbonate, supplemented with 10% fetal bovine serum, and
maintained at 37°C in 5% CO2. Cells were transfected with
siRNA using RNAinfect (Qiagen, Germantown, MD) accord-
ing to manufacturer’s instructions for adherent cells. The
efficiency of silencing was monitored by immunoblot for Ski
24 to 48 hours after transfection. All transfections were
performed with a combination of 2 21-nt double-stranded
oligonucleotides targeted against positions 910–929 (AACT-
GGCGGGCCTACATCCT) and 389–408 (AATTCTC-
CGAACGTGTCACGT) of the human Ski (DNA gene acces-
sion number NM003036) or with control siRNA directed
against the sequence AACTGGCGGGCCTACATCCT (Qia-
gen, Germantown, MD).
In Vivo Tumor Assessment
Five-week-old, male, athymic nude mice (HSD nu/
nu, Harlan-Sprague Dawley, Indianapolis, IN) were main-
tained in climate controlled conditions with 12-hour light/
dark cycles and provided water and standard chow ad libitum.
For in vivo siRNA inhibition experiments, 1  106 cells were
suspended in 100 L of endotoxin-free PBS and injected
subcutaneously into the flank. The 21-nt sequence targeting
the 389–408 region of Ski was inserted into a DNA vector
containing a RNA polymerase III promoter upstream of the
oligonucleotide sequence (Genescript, Piscataway, NJ). Be-
ginning 24 hours after tumor injection, 50 g of plasmid
vector expressing Ski-specific siRNA or control was diluted
in 1 mL of endotoxin-free PBS and hydrodynamically in-
jected via tail vein over 5 to 10 seconds 3 times per week as
described previously.23,24 Tumor volume was calculated us-
ing the formula V  /6  l  w2.
Data Analysis
All in vitro experiments were performed in triplicate.
For in vivo experiments, a minimum of 5 mice were studied
per group. Data are reported as mean  SEM. Statistical
analysis was performed by t test or Log Rank Test where
appropriate utilizing StatView software (SAS, Cary, NC). A
P value of less than 0.05 was considered significant.
RESULTS
Human Pancreatic Cancer Expresses Ski
Oncoprotein
In total, 11 human pathologically confirmed pancreatic
cancer specimens, 9 normal pancreas specimens, and 5
chronic pancreatitis specimens were stained for immunohis-
tochemical detection of Ski expression. Ski was not detected
in normal pancreas (Fig. 1A).
However, in pancreatic cancer specimens, Ski expres-
sion was increased markedly compared with normal and
chronic pancreatitis specimens and could be detected in the
cytoplasm and the nucleus of epithelial cells (Fig. 1A, C).
Chronic pancreatitis samples exhibited diffuse, weak staining
pattern that was only slightly more prominent than normal
pancreas specimens (Fig. 1A, B). Ski expression was in-
FIGURE 1. Expression of Ski in hu-
man pancreatic cancer specimens.
Normal pancreas (A) and chronic
pancreatitis specimens (B) demon-
strate no or minimal Ski expression,
respectively, when compared with
pancreatic adenocarcinoma (C) that
has diffuse background and intense
focal staining. Computer-assisted
digital quantification of Ski staining
is presented in the table. Pancreatic
cancer specimens demonstrated
significantly (P  0.05) more Ski
expression than normal pancreas
and chronic pancreatitis. B, Western
blot analysis of 9 human pancreatic
adenocarcinoma specimens demon-
strates staining for Ski in 5 of 9
samples compared with representa-
tive samples of normal (NL) pan-
creas and chronic pancreatitis (CP).
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creased markedly in pancreatic cancer compared with chronic
pancreatitis and normal pancreas specimens (Fig. 1A, table).
In addition, Ski expression was examined by immuno-
blot analysis of frozen tissue samples from normal pancreas
(n  9), chronic pancreatitis (n  5), and pancreatic cancer (n 
9) resection specimens that originated from different tumor
sources than formalin-fixed specimens (Fig. 1B). Significant
expression of Ski was detected in 5 of 9 pancreatic cancer
specimens, but not in normal pancreas or chronic pancreatitis
specimens.
Ski Expression in Pancreatic Cancer Cell Lines
The human pancreatic cancer cell line Panc-1 was
examined for expression of Ski by immunoblot analysis (Fig.
2). Although the KCI-Moh1 cell line also expressed Ski, the
Panc-1 cell line was chosen for further in vitro studies
because of strong Ski expression and known expression of
wild-type Smad4 protein.25
siRNA Targeted Against Ski Effectively
Decreases Ski Protein
Commercially available 21-nt sequences targeting Ski
were obtained, and the oligonucleotide sequence directed
against the 389–409 region of Ski was effective in gene
silencing in Panc-1 cells (data not shown). When controlled
for beta-actin loading, Ski expression was decreased 49.7% at
24 hours and was maximally decreased (71.4%) at 48 hours
(Fig. 3, lanes 2 and 3, respectively) compared with control
siRNA. Ski expression returned to baseline by 72 hours after
transfection (data not shown). These findings are consistent
with the transient nature of transfection-mediated siRNA
gene silencing. Transfection with control siRNA (Fig. 3,
lanes 4 and 5) and with scrambled, nonsilencing siRNA (data
not shown) did not decrease Ski protein expression.
Inhibition of Ski Permits TGF- Signal
Transduction
Panc-1 cells transfected with Ski siRNA (Fig. 4, right
panel), control siRNA (Fig. 4, middle panel), or no transfec-
tion (Fig. 4, left panel) were treated with TGF- and probed for
phosphorylated Smad2. Panc-1 cells were treated with TGF-
alone or with TGF- and control siRNA and exhibited only
minimal increases in the phosphorylated form of Smad2. In
contrast, inhibition of Ski via siRNA transfection resulted in a
rapid and sustained increase in phosphorylated Smad2 in the
Panc-1 cells that have nascent expression of Ski (Fig. 4, right
panel). This is consistent with functional Ski inhibition of the
TGF- signal transduction pathway in Panc-1 cells.
To determine if the changes in Smad2 phosphorylation
seen after Ski inhibition resulted in increased activity at the
level of the TGF- promoter, Panc-1 cells were transfected
with the TGF- responsive p3TP-luciferase construct. Cells
were simultaneously transfected with either Ski siRNA or
control siRNA and subsequently treated with TGF- for 24
hours. Cells transfected with control siRNA exhibited no
increase in luciferase activity compared with cells transfected
with the p3TP-luciferase construct alone. However, siRNA
inhibition of Ski resulted in a 2.5-fold increase in luciferase
activity at 24 hours (Fig. 5).
Ski Inhibition Relieves TGF--Induced p21
Expression
TGF- can regulate cellular growth control through
both apoptotic and cell cycle arrest mechanisms, depending
on the cellular target.26 We examined apoptosis in Panc-1
cells treated with TGF- for up to 72 hours and found that
inhibition of Ski through siRNA did not result in increased
apoptosis (data not shown). We examined the expression of
p21, a TGF--responsive cell cycle inhibitor, in the presence
or absence of Ski inhibition (Fig. 6). Following TGF-
stimulation alone or TGF- treatment after transfection with
control siRNA, p21 expression was low. However, cells
treated with Ski siRNA prior to TGF- administration exhib-
ited a marked increase in p21 expression by 6 hours.
FIGURE 2. Detection of Ski in vitro. Ski is endogenously ex-
pressed in both the Panc-1 and KCI-Moh1 cell lines.
FIGURE 3. Inhibition of Ski by
siRNA transfection. Panc-1 cells
were transfected with Ski-specific
siRNA (lanes 2 and 3) or control
siRNA (lanes 4 and 5). Ski expres-
sion was knocked down in cells
transfected with Ski siRNA at 48
hours (lane 3) but not in cells trans-
fected with control siRNA (lanes 4
and 5).
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Inhibition of Ski Decreases Panc-1 Growth
Both In Vitro and In Vivo
To determine if TGF- signaling associated with Ski
inhibition resulted in altered cell growth, proliferation of
Panc-1 cells was assessed by counting cells over 72 hours in
the presence or absence of TGF- (Fig. 7). Administration of
TGF- resulted in a nonsignificant decrease in growth com-
pared with control (data not shown). However, administration
of Ski siRNA prior to TGF- treatment resulted in a signif-
icant decrease in growth at 72 hours when compared with
TGF- treatment alone or with control siRNA (Fig. 7).
Panc-1 cells were injected subcutaneously into the flank
of nude mice. Mice were subsequently injected via tail vein 3
times per week for 2 weeks with control vector or the siRNA
expression vector pRNA-U6.1-Ski, a DNA vector that con-
tains the 21-nt Ski siRNA sequence downstream from an
RNA polymerase III promoter. Tumor size was recorded
FIGURE 6. TGF--induced expression of p21 following Ski inhibition. Nontransfected Panc-1 cells (left panel), those trans-
fected with control siRNA (middle panel), or Ski siRNA after 24 hours (right panel) were treated with TGF- (5 ng/mL) for 0 to
24 hours. Treatment with TGF- induced comparable increases in p21 expression in both nontransfected cells (left panel) and
cells transfected with control siRNA (middle panel). Transfection with Ski siRNA prior to TGF- administration (right panel)
was associated with an earlier and more sustained increase in p21 expression when compared with nontransfected cells and
those transfected with control siRNA.
FIGURE 4. Ski inhibition permits TGF--dependent phosphorylation of Smad2. Panc-1 cells were treated with Ski siRNA (right
panel), control siRNA (middle panel), or no transfection (left panel) for 24 hours prior to the administration of TGF- (5 ng/mL).
Immunoblots demonstrated an increase in phospho-Smad2 expression beginning as early as 30 minutes (right panel) and per-
sisting for 24 hours.
FIGURE 5. Inhibition of Ski increases TGF- transcriptional
reporter activity. Panc-1 cells were transfected with the
TGF- responsive, luciferase reporter, p3TP. TGF--induced
luciferase activity was measured in Panc-1 cells transfected
with Ski or control siRNA. Administration of TGF- (5 ng/mL)
produced no significant increase in luciferase activity over
control in these Panc-1 cells with constitutive Ski expression.
However, after siRNA inhibition of Ski, TGF- induced a sig-
nificant increase in luciferase activity (*P  0.05).
FIGURE 7. Inhibition of Ski augments TGF--induced growth
inhibition in vitro. Cells were transfected with Ski siRNA or
control siRNA or not transfected 24 hours prior to treatment
with or without TGF- (5 ng/mL; time 0). Nontransfected
cells and cells transfected with control siRNA demonstrated
similar growth curves, with a 2.5- to 3-fold increase in cell
number at 72 hours. Cells transfected with Ski siRNA,
however, demonstrated only a 50% increase in cell num-
ber (*P  0.005).
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prior to each injection (Fig. 8). In vivo delivery of the Ski
siRNA decreased tumor volume nearly 5-fold at 10 weeks.
Tumor volume was low during the treatment phase and
increased gradually during weeks 5 to 8, suggesting a pro-
longed effect of Ski siRNA. However, by week 9, growth
increased dramatically, indicating little growth inhibition
from Ski siRNA. Mice in the pRNA-U6.1-Ski group had
decreased tumor volume at the time of death compared with
control mice (data not shown).
At the conclusion of the observation period, tumors
from mice treated with pRNA-U6.1-Ski showed no change in
Ski expression compared with tumors in mice treated with
PBS or control vector (Fig. 9A, right panel). However,
tumors harvested during active treatment with pRNA-U6.1-
Ski exhibited decreased Ski expression compared with con-
trol (Fig. 9A, left panel, right lane).
After death, sections of representative tumors from
each of the treatment groups were stained with hematoxylin
and eosin. Tumors from mice treated with pRNA-U6.1-Ski
exhibited a marked increase in tumor necrosis compared with
mice treated with control vector or PBS (Fig. 9B).
DISCUSSION
Pancreatic cancer is a biologically aggressive, highly
metastatic tumor that, at presentation, has frequently spread
beyond the limits of curative resection and is refractory to
current chemotherapeutic regimens. The molecular character-
istics of pancreatic cancer that confer sustained growth,
metastatic potential, and chemotherapeutic resistance are un-
known. Several molecular genetic defects have been profiled
in pancreatic cancer, and alterations in the TGF- pathway
have been among the most prevalent. Defects in TGF-
signal transduction are common in many gastrointestinal
tumors, and the oncoprotein Ski has been identified recently
as a negative regulator of this pathway and correlated with a
less favorable outcome in several human malignancies.16,17
The aim of this study was to determine if Ski expression
occurred in human pancreatic adenocarcinoma and to inves-
tigate the significance of this protein in modulating tumor
growth. We found that expression of Ski occurred in human
pancreatic cancer resection specimens, and inhibition of Ski
decreased pancreatic tumor growth both in vitro and in vivo.
FIGURE 8. Inhibition of Ski decreases tumor growth and en-
hances survival in vivo. Mice treated with Ski siRNA expres-
sion vector demonstrated a 5-fold decrease in tumor volume
at 10 weeks (*P  0.001).
FIGURE 9. Ski siRNA expression
vector decreases tumor levels of Ski
and is associated with increased
tumor necrosis. A, In tumors from
mice treated with Ski siRNA ex-
pression vector, tissue levels of Ski
were decreased when compared
with control. At the conclusion of
treatment (right panel), no sub-
stantial decrease in Ski protein ex-
pression in the experimental group
was noted. B, Representative sec-
tions of tumor taken at the conclu-
sion of treatment from mice treated
with control vector (left) or Ski
siRNA expression vector (right)
were stained with hematoxylin and
eosin. Tumor from mice treated
with Ski siRNA expression vector
demonstrated an increase in tumor
necrosis when compared with con-
trol samples.
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Furthermore, Ski inhibited TGF- signaling, in part, through
inhibition of Smad2 phosphorylation. In addition, inhibition
of Ski increased p21 expression in response to TGF-,
thereby implicating impaired cell cycle regulation in Ski-
expressing tumors.
The importance of the TGF- signaling pathway in the
progression of pancreatic cancer has been well studied. Sev-
eral in vitro studies of this pathway have confirmed that
attenuation of the TGF--induced Smad signaling pathway
leads to resistance to growth arrest,27 and restoration of
Smad4 reverses the invasive phenotype of pancreatic adeno-
carcinoma cells.28 Additionally, restoration of TGF- signal-
ing in MIA PaCa-2 cells sensitizes these cells to ionizing
radiation.29 Importantly, recent evidence suggests that an
intact TGF- signal transduction pathway results in improved
outcomes in patients with pancreatic cancer. The expression
of TGF- and its downstream effector, p21, has been shown
to identify a subset of patients with significantly increased
survival compared with those with tumors that do not express
either protein.30 In addition, expression of Smad4 has been
associated with improved outcome in patients with pancreatic
adenocarcinoma.31 Ski has been identified in several nonpan-
creatic human malignancies, and its role in tumor biology and
disease progression has been increasingly appreciated. Ski
expression was identified in each of 44 human melanoma
specimens examined, and a stable transfectant expressing an
antisense Ski vector demonstrated increased growth inhibi-
tion in the presence of TGF- when compared with control
cells.15 In colorectal cancer, Ski expression was found in 10%
of colorectal tumor biopsies and independently predicted
decreased disease-free and overall survival.32 Moreover, ex-
pression of Ski has been found to correlate with depth of
invasion and pathologic stage in esophageal cancer.16 Addi-
tionally, in a subset of patients with esophageal cancer and
low TGF- expression, expression of Ski predicted decreased
overall survival.16
The molecular mechanisms by which Ski promotes
tumor growth are not completely understood. Previous work
has demonstrated that its biologic actions are mediated
through binding a consensus GTCTAGAC sequence of
Smads2, 3, and 4.33 Ski-Smad complex formations may be
associated with impaired phosphorylation or cytoplasmic
trafficking of Smad proteins. Also, a Ski-Smad complex may
trigger proteosomal degradation and loss of the TGF--
mediated signal.34 Although nuclear expression of Ski is low,
it may function to bind important Smad complex cofactors
and inhibit DNA binding and transcriptional activation.
Whether the abrogation of the TGF- signal is largely de-
pendent on inhibition of Smad2 phosphorylation, cytoplasmic
sequestration of Smad 2/3/4, interference with nuclear cofac-
tor assembly, or a combination of these mechanisms has not
been determined. Alternatively, progression of melanoma has
been associated with Ski activation of the Wnt/beta-catenin
pathway, which resulted in transcription of microphthalmia-
associated transcription factor and Nr-CAM that were asso-
ciated with melanoma cell growth and increased motility.35
Importantly, in human melanoma, Ski expression is corre-
lated with cell cycle progression by repressing the activity of
protein RB and by decreasing Smad-mediated induction of
p21.36 Given the importance of defects in the TGF--induced
Smad signaling pathway in human malignancy, a negative
regulator of this pathway, such as Ski, could act as functional
knockout of the Smad 2/3/4 signaling complex and contribute
to disease progression.
These findings suggests that Ski expression occurs
frequently in human pancreatic adenocarcinoma and contrib-
utes to tumor growth through inhibition of TGF- signaling
both in vitro and in vivo through inhibition of Smad signal-
ing. The inhibition of Smad signaling by Ski may be medi-
ated by inhibition of Smad phosphorylation or transcriptional
cofactor assembly. These molecular events may permit
changes in cell cycle regulation. This study provides depth to
the field of study of TGF- effects in pancreatic cancer and
proof of principle that alterations in the TGF- growth
control pathway can occur through multiple mechanisms. As
the science of TGF-, Smad, and Ski advance in pancreatic
adenocarcinoma, potential diagnostic, prognostic, and thera-
peutic tools are on the horizon.
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